Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Hepatorenal Syndrome Market Set To Climb From $1.46 Billion In 2026 To $1.91 Billion By 2030
The hepatorenal syndrome market has experienced substantial growth in recent years. It is anticipated to increase from $1.37 billion in 2025 to $1.46 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. This historical expansion is attributable to several factors, including the increasing prevalence of chronic liver disease, a rising incidence of cirrhosis-related complications, the expansion of intensive care unit infrastructure, enhanced clinical awareness of HRS diagnosis, and the availability of vasoconstrictor-based therapies.
The hepatorenal syndrome market is poised for significant expansion in the upcoming years, with projections indicating it will reach $1.91 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. This anticipated growth stems from several factors, including an increase in liver transplant procedures, a greater focus on early-stage HRS detection, the broader deployment of advanced renal support therapies, the increasing adoption of precision medicine approaches, and elevated investment in hepatology-focused clinical research. Furthermore, notable trends anticipated during this period include the rising use of targeted vasoconstrictor therapies, an expanded application of early diagnostic biomarkers, a heightened emphasis on multidisciplinary critical care management, the growth of albumin-based combination treatments, and enhanced monitoring of renal function in patients with liver disease.
Get A Free Sample Report With In-Depth Market Insights:
Hepatorenal Syndrome Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The increasing incidence of liver diseases is anticipated to fuel the growth of the hepatorenal syndrome market. Liver diseases encompass conditions that compromise liver function, such as hepatitis, cirrhosis, fatty liver, liver cancer, genetic disorders, and autoimmune diseases, often exacerbated by factors like obesity, diabetes, alcohol consumption, viral infections, poor nutrition, and exposure to toxins. The rise in these liver conditions, particularly cirrhosis and acute liver failure, elevates the likelihood of hepatorenal syndrome (HRS) by inducing severe hemodynamic and kidney dysfunction resulting from progressive liver damage. For instance, in April 2024, the Office for Health Improvement & Disparities (OHID) in the UK reported that hospital admissions for liver disease in the UK climbed to 155.2 per 100,000 in 2023, an increase from 150.6 per 100,000 in 2022. Consequently, the growing occurrence of liver diseases is a significant factor propelling the expansion of the hepatorenal syndrome market.
Hepatorenal Syndrome Market Segment Analysis And Revenue Potential
The hepatorenal syndrome market covered in this report is segmented –
1) By Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome, Other Types
2) By Treatment: Liver Transplantation, Terlipressin Infusion, Albumin Infusion, Hemodialysis, Vasoconstrictors
3) By Diagnosis: Liver Function Tests, Urinalysis And Urine Electrolytes, Other Diagnoses
4) By End Users: Hospitals, Specialty Clinics
Subsegments:
1) By Type 1 Hepatorenal Syndrome: Acute Kidney Injury-Associated HRS, Rapidly Progressive Renal Failure
2) By Type 2 Hepatorenal Syndrome: Chronic Kidney Dysfunction-Associated HRS, Slowly Progressive Renal Failure
3) By Other Types: HRS With Cirrhosis, HRS With Acute Liver Failure, HRS With Alcoholic Hepatitis
Hepatorenal Syndrome Market Innovation Trends: What Developments Are Reshaping The Industry?
Companies operating in the hepatorenal syndrome market are concentrating on developing innovative devices, such as cytopheretic devices, to enhance patient outcomes by lowering inflammation, stabilizing kidney function, and boosting the effectiveness of Hepatorenal Syndrome (HRS) treatments. The cytopheretic device (Cytosorb) is an extracorporeal blood purification therapy specifically designed to reduce systemic inflammation and immune activation in critically ill patients, including those with Hepatorenal Syndrome (HRS). For instance, in October 2023, SeaStar Medical Holding Corporation, a US-based medical device company, secured FDA approval for its Selective Cytopheretic Device (SCD) for the treatment of hepatorenal syndrome (HRS). This advanced, cell-directed therapy targets hyperinflammation, a primary factor contributing to kidney dysfunction in patients with acute-on-chronic liver failure. By employing immunomodulation, SCD assists in regulating abnormal immune responses, potentially supporting kidney recovery and improving patients’ eligibility for life-saving liver transplants. Its effectiveness in enhancing solid organ function has been demonstrated through preclinical and clinical studies across conditions such as sepsis, acute kidney injury (AKI), and cardiorenal syndrome.
Hepatorenal Syndrome Market Key Players Shaping Industry Direction
Major companies operating in the hepatorenal syndrome market are Eli Lilly and Company, Baxter International Inc., Mallinckrodt Pharmaceuticals, Ferring Pharmaceuticals Ltd, La Jolla Pharmaceutical Company, Teva Pharmaceutical Industries Ltd, Cumberland Pharmaceuticals Inc., Innoviva Specialty Therapeutics Inc, BioVie Inc., SeaStar Medical, Otsuka Pharmaceutical Co. Ltd, Pfizer Inc., AbbVie Inc., Bristol Myers Squibb, Novartis AG, Sanofi, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Bayer AG, AstraZeneca
View The Full Hepatorenal Syndrome Market Report:
Hepatorenal Syndrome Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the hepatorenal syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatorenal syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
